Answers are grounded in this paper and cite their sources.
Ductal carcinoma in situ (DCIS) presents a variable risk of progression to invasive ductal carcinoma (IDC), yet reliable predictors of this transition are limited. Membrane type I matrix metalloproteinase (MT1-MMP) is a key regulator of this progression. We combined RNA sequencing of MT1-MMPhigh and MT1-MMPlow cell populations from intraductal tumor xenografts with human high-grade DCIS datasets to identify regulators of early breast cancer progression. Data from 1100 breast cancer patients in The Cancer Genome Atlas (TCGA) were analyzed (Pearson's correlation). Protein expressions were analyzed by IHC on three independent human cohorts (n = 231, Friedman test). siRNA-mediated knockdown of Secreted Protein Acidic and Cysteine Rich (SPARC) and pharmacological inhibition of TGF-β receptor type I (TGFBR), gelatin degradation and cell migration assays were employed to analyze the role of the TGFBRI–SPARC–MT1-MMP axis in breast cancer invasion (ANOVA). A new intraductal syngeneic mice model was used for testing TGFBRI inhibitors in the DCIS-to-IDC transition (ANOVA). SPARC was identified as an invasive switch candidate, upregulated in DCIS versus normal epithelium, further increased in IDC, and correlated with MT1-MMP expression. Functionally, SPARC depletion reduced MT1-MMP, matrix degradation, and TGF-β signaling. TGFBRI inhibition decreased SPARC and MT1-MMP levels, matrix degradation, cell migration, and DCIS-to-IDC transition in a triple-negative intraductal syngeneic mouse model. Notably, SPARC did not associate with metastasis, confirming its specific role in early progression. Our findings highlight the TGFBRI–SPARC–MT1-MMP axis as a promising therapeutic target for preventing early breast cancer invasion.
No takes yet. Share an insight, caveat, or question.
Sciacca et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: